Artelo Biosciences (ARTL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Jul, 2026Executive summary
Annual meeting scheduled for July 17, 2026, with voting open until July 16, 2026.
Shareholders of record as of May 22, 2026, are eligible to vote on key matters.
Voting can be conducted online, by phone, or at the virtual meeting.
Voting matters and shareholder proposals
Shareholders are encouraged to vote on important issues impacting their investment.
Voting instructions and access to proxy materials have been provided to eligible shareholders.
Shareholder rights and capital structure
Only holders of common shares as of the record date are entitled to vote.
Each shareholder receives a unique control number to access voting and meeting materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Artelo Biosciences
- All proposals, including director elections and share increases, were approved.ARTL
AGM 202617 Jul 2026 - Shareholders urged to vote before July 17, 2026, to ensure quorum and efficient meeting conduct.ARTL
Proxy filing16 Jul 2026 - Shareholders will vote on director elections, share authorization, and a major equity issuance.ARTL
Proxy filing2 Jul 2026 - Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 202430 Jun 2026 - Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTL
Proxy filing22 Jun 2026 - Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTL
Corporate presentation5 Jun 2026 - Vote on director elections and a major increase in authorized shares at the 2026 annual meeting.ARTL
Proxy filing5 Jun 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing5 Jun 2026 - Lead drug candidates show strong progress in major markets with robust safety and efficacy data.ARTL
Corporate presentation26 May 2026